Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) logo

Product menu

Female patient looking to camera

COPD triple therapy guidance for UK healthcare professionals | Trelegy Ellipta

UK and global COPD guidelines recommend stepping up to triple therapy for appropriate patients who remain symptomatic or exacerbating on dual therapy.

Explore how Trelegy Ellipta aligns with current NICE and GOLD treatment pathways.1,2

Register on GSKPro to explore full healthcare professional resources.

Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid (ICS) and a long-acting β2-agonist (LABA) or a combination of a LABA and a long-acting muscarinic antagonist (LAMA).3

Icon of lungs

When to consider triple therapy in COPD

Explore the clinical rationale and evidence behind stepping up from dual therapy to triple therapy in appropriate patients.

Learn more

Ellipta icon

Inhaler technique and treatment simplicity

Understand how consistent inhaler technique and patient‑centred device design can support COPD management.

Register to find out more

COPD pathway icon

Where triple therapy fits in the COPD pathway​

See how triple therapy fits within guideline‑led COPD management and treatment escalation.

Register to explore

References:

  1. COPD in over 16s: diagnosis and management NICE guideline [NG115]. Last updated: July 2019.
  2. GOLD. Global Strategy for the Diagnosis, Management and Prevention of COPD. 2026 Report.
  3. Trelegy Ellipta Summary of Product Characteristics.

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to GSK on 0800 221 441 or UKSafety@gsk.com.

May 2026 | PM-GB-FVU-WCNT-260002 (V1.0)